BOSTON--(BUSINESS WIRE)--June 27, 2006--Point Therapeutics, Inc. (NASDAQ: POTP - News) presented a preclinical poster on the Company’s lead diabetes compound, PT-630, at the Endocrine Society Annual Meeting on Monday, June 26, 2006. PT-630 is an inhibitor of DPP-4, which is a widely recognized target for the treatment of diabetes. During this poster presentation, the Company presented side-by-side experiments in Zucker Diabetic Fatty (ZDF) rats comparing PT-630 to both a cyanopyrrolidine (CP) DPP-4 inhibitor and to metformin. These preclinical data lead the Company to conclude that:
